Mounjaro vs. Contrave
Mounjaro and Contrave differ in both mechanism and primary use. Mounjaro, a dual GIP and GLP-1 agonist, is for type 2 diabetes management and provides significant HbA1c reductions and moderate weight loss. Contrave, a combination of naltrexone and bupropion, targets weight management, delivering moderate weight loss. Side effects differ: Mounjaro causes nausea, while Contrave may lead to mood changes and insomnia. Mounjaro costs $1,135/month, significantly higher than Contrave’s $300/month. Neither drug currently faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Bupropion enhances dopamine and norepinephrine activity, reducing appetite and cravings; Naltrexone modulates the brain’s reward system, reducing cravings and emotional eating behaviors by blocking opioid receptors.
Common Side Effects
Nausea, constipation, headache, dizziness, dry mouth, and insomnia.
Serious Potential Side Effects
Increased blood pressure, seizures (rare), suicidal thoughts, and liver damage.